Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency Announced at the 2019 SSIEM Symposium
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today presented positive 20-dose data on 14 patients from the Company’s completed Phase 1/2 trial and ongoing Phase 2 open-label extension (OLE) trial for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM).
“The arginine control I have seen in my patients continues to be impressive,” stated Dr. George Diaz, Division Chief of Medical Genetics in the Department of Genetics & Genomic Sciences at the Icahn School of Medicine at Mt. Sinai, New York, NY in a press release. “I’m very encouraged by the improvements in mobility we observed in these patients after 20 doses. I believe the Phase 3 PEACE trial is well designed to capture these changes.”
Read the full press release here.
Source: Aeglea BioTherapeutics
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809